Document Classification

Section Type: RESULTS

Text: By contrast, other predefined secondary outcomes were much the same in both groups-viral suppression (< 40 copies per mL ; 465 [49 %] of 952 measurements in CLIN vs 456 [52 %] of 884 in LAB), HIV resistance (23 [10 %] of 238 participants vs 22 [10 %] of 219 participants), mortality (44 [18 %] of 238 vs 32 [14 %] of 221), disease progression (85 [36 %] of 238 vs 64 [29 %] of 221), adherence (672 [63 %] of 1067 measurements vs 621 [61 %] of 1011), loss to follow-up (21 [9 %] of 238 vs 17 [8 %] of 221), and toxic effects (46 [19 %] of 238 vs 56 [25 %] of 221).